Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Spotlight on Proffered Papers 3

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4
Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
Geraldine O'Sullivan Coyne
National Cancer Institute, Bethesda, MD, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 11:50 AM-12:30 PM
Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
Alan Ho
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 11:50 AM-12:30 PM
Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors
Anthony W. Tolcher
NEXT Oncology, San Antonio, TX, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 11:50 AM-12:30 PM
Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo
Christopher J Schulze
Revolution Medicines, Redwood City, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 11:50 AM-12:30 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4